{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"24.8","upperLimit":"103.8","value":"58.6"},{"groupId":"OG001","lowerLimit":"14.3","upperLimit":"28.4","value":"19.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"145"}],"units":"Participants"}],"description":"Disease Free Survival (DFS) is defined as the time from a Complete Response (CR) until death or relapse. The date of last clinical assesment will be used as the censor date for patients with no death or relapse. The DFS will be estimated using the Kaplan-Meier method with confidence intervals presented.","dispersionType":"95% Confidence Interval","groups":[{"description":"See detailed description or participant flow.","id":"OG000","title":"Phase I - Alemtuzumab and Combination Chemotherapy"},{"description":"See detailed description or participant flow.","id":"OG001","title":"Phase II - Alemtuzumab and Combination Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"All patients who received protocol treatment and had a complete response (CR) during treatment were included in this analysis. Phase I patients, who achieved complete response, were included with the phase II patients, who achieved complete response, for this analysis.","reportingStatus":"POSTED","timeFrame":"9 years 4 months","title":"Disease-free Survival, for Only Complete Response Patients","type":"SECONDARY","unitOfMeasure":"months"}